(Q73481742)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209732%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

Clozapine treatment of persistent paroxysmal dyskinesia associated with concomitant paroxetine and sumatriptan use (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209732%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

main subject

Paroxysmal dyskinesia

1 reference

Abraham JT

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209732%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Brown R

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209732%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Meltzer HY

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209732%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 July 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209732%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

published in

Biological Psychiatry

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209732%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209732%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209732%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

144-146

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209732%20AND%20SRC:MED&resulttype=core&format=json

Fluoxetine, fluvoxamine and extrapyramidal tract disorders

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

The safety of concomitant use of sumatriptan and antidepressant treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

Fluoxetine and extrapyramidal side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

Persistent dyskinesia in a patient receiving fluoxetine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

Metoclopramide side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

Clozapine: neuroleptic-induced EPS and tardive dyskinesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

Neuropharmacological studies on the nigro-striatal and raphe-striatal system in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

Fluoxetine and extrapyramidal symptoms in CNS lupus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

The Clinical Pharmacology, Pharmacokinetics and Metabolism of Sumatriptan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

Tardive dyskinesia--reversible and persistent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

Treatment of the serotonin syndrome with cyproheptadine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

The effects of clozapine on tardive dyskinesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

Sertraline and extrapyramidal side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

Extrapyramidal symptoms upon discontinuation of fluoxetine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

Inhibition of the electrically induced release of [3H]dopamine by serotonin from superfused rat striatal slices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900248-5

10.1016/S0006-3223(97)00248-5

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209732%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference